multiple myeloma

     

Select            
Trial Studied trt Control trt patientstagsROB Trial resultdeath (overall survival) progression or death (progression free survival PFS)

All mechanism

not classified
CLARION    NCTcarfilzomib -
NCT01863550    NCTcarfilzomib -
ELOQUENT - 1    NCT Elotuzumab Lenalidomide Dexamethasone Lenalidomide + Dexamethasone Risk of bias -
ELOQUENT - 2    NCTElotuzumab Lenalidomide Dexamethasone Lenalidomide + Dexamethasone -
MRC Myeloma IX     CTDaMP -
MM-015      NCTMPR+RMP -
IFM 01/01     MPTMP -
IFM 99/06      NCTMPTMP -
NCT01274403      NCTMPTMP -
GIMEMA      NCTMPT+TMP -
HOVON 49     MPT+TMP -
NMSG     MPT+TMP -
TMSG      NCTMPT+TMP -
VISTA      NCTVMPMP -
FIRST      NCTRd ou Rd18MPT -
EIA06 (NCT00602641)    NCTMPR+RMPT+T -
NR 1997   PCAB+IFN-2aPCAB -
ASPIRE, 2015      NCTcarfilzomib placebo (on top lenalidomide and dexamethasone)Risk of bias suggesting-21%
ELOQUENT 2, 2015      NCTelotuzumab placebo (on top lenalidomide and dexamethasone)Risk of bias negative-19%
NR 2013   MPR + CPRRd -
NCT00911859      NCTVMP + siltuximabVMP -
NR 2010     VMPT+VTVMP -

immune checkpoint inhibition

pembrolizumab
KEYNOTE-185, 2018    NCTpembrolizumab, lenalidomide, dexametahsonelenalidomide, dexamethasonenot eligible for ASCTRisk of bias remark
KEYNOTE-183, 2018    NCTpembrolizumab + pomadoline + dexamethasonepomadoline + dexamethasonerrMMRisk of bias negative

proteasome inhibitor

carfilzomib
ENDEAVOR, 2016          NCTcarfilzomibbortezomibrelapsed MMRisk of bias suggesting-21%-47%
ECOG-ACRIN    NCTcarfilzomibbortezomid -
CLARION    NCTcarfilzomibbortezomid -
ASPIRE, 2014            NCTcarfilzomib lenalidomide dexamethasonelenalidomide and dexamethasone alonerelapsed MMRisk of bias suggesting-21%-31%
FOCUS, 2017        NCTcarfilzomiblow-dose corticosteroids relapsed and refractory multiple myeloma (RRMM)Risk of bias negative-3%